Monthly or quarterly dosing can simplify life with migraine.

Appeal Your Ajovy Denial

Ajovy is one of several CGRP antibodies—appeals can justify why it’s the right one for you.

Understanding Your Ajovy for Migraine Prevention Denial

Ajovy may be denied when insurers want you to try a different CGRP antibody or insist that older preventives are enough. Appeals should highlight your specific needs and prior experiences.

Common Reasons for Denial

  • ! Failure to use insurer-preferred CGRP agent first
  • ! Not meeting threshold for chronic or high-frequency migraine
  • ! Incomplete documentation of prior preventive failures
  • ! Questions about monthly vs. quarterly dosing

How We Help

We help your clinician explain why Ajovy’s dosing schedule, response in your case, or side-effect profile makes it the most appropriate option.

Some Types of Evidence We Can Use For Supporting Your Appeal

Fremanezumab reduces migraine frequency in both episodic and chronic migraine.

Flexible monthly or quarterly dosing can support adherence and patient preference.

CGRP monoclonal antibodies are recommended for patients with frequent migraines who fail standard preventives.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Ajovy Savings Offer

Pay as little as $15 per prescription with commercial insurance. Annual limits apply.

Teva Cares Foundation

Free medication for qualifying uninsured or underinsured patients meeting income criteria.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

American Migraine Foundation

Leading resource for migraine education, support, and advocacy.

National Headache Foundation

Promotes headache awareness and education, and provides patient resources.

Alliance for Headache Disorders Advocacy

Advocates for equitable policies for people with headache disorders.

Frequently Asked Questions

Yes. Your appeal should specify which pattern you have and reference data showing Ajovy’s benefit in that group.

Absolutely. If quarterly dosing improves adherence or reduces burden, your clinician should spell that out.

Ready to Fight Your Ajovy for Migraine Prevention Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.